Abstract
β-thalassaemia is one of the most common single-gene inherited conditions in the world, and thalassaemia carrier screening is the most widely performed genetic screening test, occurring in many different countries. β-thalassaemia carrier screening programmes provide a unique opportunity to compare the delivery of carrier screening programmes carried out in different cultural, religious and social contexts. This review compares the key characteristics of β-thalassaemia carrier screening programmes implemented in countries across the world so that the differences and similarities between the programmes can be assessed. The manner in which thalassaemia carrier screening programmes are structured among different populations varies greatly in several aspects, including whether the programmes are mandatory or voluntary, the education and counselling provided and whether screening is offered pre-pregnancy or antenatally. National and international guidelines make recommendations on the most appropriate ways in which genetic carrier screening programmes should be conducted; however, these recommendations are not followed in many programmes. We discuss the implications for the ethical and acceptable implementation of population carrier screening and identify a paucity of research into the outcomes of thalassaemia screening programmes, despite the fact that thalassaemia screening is so commonly conducted.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Mennuti MT : Genetic screening in reproductive health care. Clin Obstet Gynecol 2008; 51: 3–23.
Genetic Screening: Ethical Issues. London: Nuffield Council on Bioethics, 1993.
Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Services, World Health Organization, 1998.
Raffle AE : Information about screening- is it to achieve high uptake or to ensure informed choice? Health Expect 2001; 4: 92–98.
Wilson JMG, Jugner G : Principles and Practice of Screening for Disease. Geneva, World Health Organization, 1968.
Alwan A, Modell B, with contributions from, Bittles A, Czeizel A, Hamamy H: Community control of genetic and congenital disorders. WHO, EMRO Technical Publications Series 24: 1997.
Marteau TM, Dormandy E, Michie S : A measure of informed choice. Health Expect 2001; 4: 99–108.
Trent RJA : Diagnosis of the Haemoglobinopathies. Clin Biochem Rev 2006; 27: 27–38.
Tarazi I, Al Najjar E, Lulu N et al: Obligatory premarital tests for β-thalassaemia in the Gaza Strip: evaluation and recommendations. Int Jnl Lab Hem 2007; 29: 111–118.
Xu XM, Zhou YQ, Lou GX et al: The prevalence and spectrum of α and β thalassaemia in Guangdong Province: implications for the future health burden and population screening. J Clin Pathol 2004; 57: 517–522.
Bain B : Haemoglobin and the Genetics of Haemoglobin Synthesis: Haemoglobinopathy Diagnosis. London, Blackwell Publishing, 2005, 2nd edn.
Marengo-Rowe AJ : The thalassemias and related disorders. Proc (Bayl Univ Med Cent) 2007; 20: 27–31.
Yong KN, Wadsworth LD, Langlois S et al: Thalassemia carrier screening and prenatal diagnosis among the British Columbia (Canada) population of Chinese descent. Clin Genet 1999; 55: 20–25.
ACOG: ACOG Practice Bulletin- Clinical Management Guidelines for Obstetricians-Gynecologists- Hemoglobinopathies in Pregnancy. Obstet Gynecol 2007; 109: 229–237.
Abolghasemi H, Amid A, Zeinali S et al: Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol 2007; 29: 233–238.
Modell B, Khan M, Darlison M et al: A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ 2001; 79: 1006–1013.
Birgens H, Ljung R : The thalassaemia syndromes. Scand J Clin Lab Invest 2007; 67: 11–26.
Rund D, Rachmilewitz E : Medical progress: (beta)- Thalassemia. N Engl J Med 2005; 353: 1135–1146.
Metcalfe SA, Barlow-Stewart K, Campbell J et al: Genetics and blood: Haemoglobinopathies and clotting disorders. Australian Family Physician 2007; 36: 812–819.
AlHamdan NA, AlMazrou YY, AlSwaidi FM et al: Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genetics in Medicine 2007; 9: 372–377.
Ghotbi N, Tsukatani T : Evaluation of the national health policy of thalassaemia screening in the Islamic Republic of Iran. La Revue de Sante de la Mediterranee orientale 2005; 11: 308–318.
Karimi M, Jamalian N, Yarmohammadi H et al: Premarital screening for β-thalassaemia in Southern Iran: options for improving the programme. J Med Screen 2007; 14: 62–66.
Khorasani G, Kosaryan M, Vahidshahi K et al: Results of the national program for prevention of -Thalassemia major in the Iranian province of Mazandaran. Hemoglobin 2008; 32: 263–271.
Samavat A, Modell B : Iranian national thalassaemia screening programme. BMJ 2004; 329: 1134–1137.
Angastiniotis MA, Hadjiminas MG : Prevention of thalassaemia in Cyprus. Lancet 1981; 1: 369–371.
Cowan RS : Moving up the slippery slope: mandated genetic screening on Cyprus. Am J Med Genet C Semin Med Genet 2009; 151C: 95–103.
Mitchell JJ, Capua A, Clow C et al: Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and β-Thalassemia disease carriers in high schools. Am J Med Genet 1996; 59: 793–798.
Zlotogora J, Carmi R, Lev B et al: A targeted population carrier screening program for severe and frequent genetic diseases in Israel. Eur J Hum Genet 2009; 17: 591–597.
Vallance H, Ford J : Carrier testing for Autosomal-Recessive disorders. Critical Reviews in Clinical Laboratory Sciences 2003; 40: 473–497.
Colah R, Surve R, Wadia M et al: Carrier screening for β-Thalassemia during pregnancy in India: a 7-year evaluation. Genet Test 2008; 12: 181–186.
Atkin K, Ahmad WIU : Genetic screening and haemoglobinopathies: ethics, politics and practice. Soc Sci Med 1998; 46: 445–448.
Locock L, Kai J : Parents’ experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era. Br J Gen Pract 2008; 58: 161–168.
NHS Sickle Cell and Thalassaemia Screening Programme. vol. 2010, Accessed at: http://www.sct.screening.nhs.uk.
Old JM : Screening and genetic diagnosis of haemoglobinopathies. Scand J Clin Lab Invest 2007; 67: 71–86.
Delatycki MB : Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Research and Human Genetics 2008; 11: 422–430.
Ahmed S, Green J, Hewison J : What are Pakistani women's experiences of antenatal carrier screening for beta-thalassaemia in the UK? Why it is difficult to answer this question? Public Health 2002; 116: 297–299.
Ahmed S, Green J, Hewison J : Antenatal thalassaemia carrier testing: women's perceptions of ‘information’ and ‘consent’. J Med Screen 2005; 12: 69–77.
Metcalfe SA, Barlow-Stewart K, Delatycki MB et al: Population genetic screening. Australian Family Physician 2007; 36: 794–800.
Ormand KE, Iris M, Banuvar S et al: What do patients prefer: informed consent models for genetic carrier testing. Journal of Genetic Counselling 2007; 16: 539–550.
The Royal Women's Hospital Maternity Clinical Practice Guidelines. vol. 2010, Accessed at: http://www.thewomens.org.au/MaternityClinicalPracticeGuidelines.
Ong LML, de Haes JCJM, Hoos AM et al: Doctor-patient communication: a review of the literature. Soc Sci Med 1995; 40: 903–918.
Armeli C, Robbins SJ, Eunpu D : Comparing knowledge of β-thalassemia in samples of Italians, Italian-Americans, and non-Italian-Americans. Journal of Genetic Counseling 2005; 14: 365–376.
Firdous N : Prevention of thalassaemia and haemoglobinopathies in remote and isolated communities-The Maldives experience. Ann Hum Biol 2005; 32: 131–137.
Chadwick R, ten Have H, Husted J et al: Genetic screening and ethics: European perspectives. J Med Philos 1998; 23: 255–273.
Andermann A, Blancquaert I, Beauchamp S et al: Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86: 317–319.
Scriver CR, Bardanis M, Cartier L et al: β-Thalassemia disease prevention: genetic medicine applied. Am J Med Genet 1984; 36: 1024–1038.
Gilani AL, Jadoon AS, Qaiser R et al: Attitudes towards genetic diagnosis in Pakistan: a survey of medical and legal communities and parents of thalassemic children. Community Genetics 2007; 10: 140–146.
Mudiyanse RM : Thalassemia treatment and prevention in Uva province, Sri Lanka: a public opinion survey. Hemoglobin 2006; 30: 275–289.
Godard B, Ten Kate L, Evers-Kiebooms G et al: Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 2003; 11 (Suppl 2): S49–S87.
Cao A, Rosatelli MC, Galanello R : Control of beta-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience. Ciba Found Symp 1996; 197: 137–151.
Keskin A, Turk T, Polat A et al: Premarital screening of beta-thalassaemia trait in the province of Denizli, Turkey. Acta Haematol 2000; 104: 31–33.
Greengross P, Hickman M, Gill M et al: Outcomes of universal antenatal screening for haemoglobinopathies. J Med Screen 1999; 6: 3–10.
Bain BJ, Chapman C : A survey of current United Kingdom practice for antenatal screening for inherited disorders of globin chain synthesis. UK Forum for Haemoglobin Disorders. J Clin Pathol 1998; 51: 382–389.
Liao C, Mo Q, Li J et al: Carrier screening for α- and β-thalassemia in pregnancy: the results of an 11-year prospective program in Guangshou Maternal and Neonatal hospital. Prenat Diagn 2005; 25: 163–171.
Lena-Russo D, Badens C, Aubinaud M et al: Outcome of a school screening programme for carriers of haemoglobin disease. J Med Screen 2002; 9: 67–69.
Stone C, Lester R : Beyond the crystal ball: the epidemiology of some genetic conditions in victoria. Melbourne, Public Health Group, Department of Human Services 2002.
Scriver CR : Community genetics and dignity in diversity in the Quebec network of genetic medicine. Commun Genet 2006; 9: 142–152.
Bozkurt G : Results from the north Cyprus thalassaemia prevention program. Hemoglobin 2007; 31: 257–264.
Bate CM : Thalassaemia in Cyprus. Proc roy Soc Med 1975; 68: 514–516.
Hoedemaekers R, Have HT : Geneticization: the Cyprus paradigm. J Med Philos 1998; 23: 274–287.
Chern JPS, Lin K, Su Y et al: Impact of a national β-Thalassemia carrier screening program on the birth rate of Thalassaemia major. Pediatric Blood Cancer 2006; 46: 72–76.
Davies SC, Cronin E, Gill M et al: Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000; 4.
Green JM, Hewison J, Bekker HL et al: Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technol Assess 2004; 8.
Metcalfe SA, Aitken M, Gaff CL : The importance of program evaluation: how can it be applied to diverse genetics education settings? Journal of Genetic Counseling 2008; 17: 170–179.
Theodoridou S, Alemayehou M, Prappas N et al: Carrier Screening and Prenatal Diagnosis of Hemoglobinopathies. A Study of Indigenous and Immigrant Couples in Northern Greece, Over the Last 5 Years. Hemoglobin 2008; 32: 434–439.
Cao A, Furbetta M, Galanello R et al: Prevention of Homozygous β-Thalassemia by Carrier Screening and Prenatal Diagnosis in Sardinia. Am J Med Genet 1981; 33: 592–605.
Cao A, Rosatelli MC, Leoni GB et al: Antenatal diagnosis of beta-thalassemia in Sardinia. Ann N Y Acad Sci 1990; 612: 215–225.
Chern JPS, Lin K, Lu M et al: β-Thalassaemia Major Births After National Screening Program in Taiwan. Pediatric Blood Cancer 2008; 50: 58–61.
Sirdah M, Bilto YY, El Jabour S, Najjar K : Screening secondary school students in the Gaza strip for β-thalassaemia trait. Clin Lab Haem 1998; 20: 279–283.
Acemoglu H, Beyhun NE, Vancelik S, Polat H, Guraksin A : Thalassaemia screening in a non-prevalent region of a prevalent country (Turkey): is it necessary? Public Health 2008; 122: 620–624.
Canatan D, Kose MR, Ustundag M, Haznedaroglu D, Ozbas S : Hemoglobinopathy Control Program in Turkey. Community Genetics 2006; 9: 124–126.
Al Sulaiman A, Suliman A, Al Mishari M, Al Sawadi A, Owaidah TM : Knowledge and attitude toward the hemoglobinopathies premarital screening program in Saudi Arabia: population-based survey. Hemoglobin 2008; 32: 531–538.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Cousens, N., Gaff, C., Metcalfe, S. et al. Carrier screening for Beta-thalassaemia: a review of international practice. Eur J Hum Genet 18, 1077–1083 (2010). https://doi.org/10.1038/ejhg.2010.90
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ejhg.2010.90
Keywords
This article is cited by
-
Carrier burden of over 300 diseases in Han Chinese identified by expanded carrier testing of 300 couples using assisted reproductive technology
Journal of Assisted Reproduction and Genetics (2023)
-
Adolescents’ experiences and views of the national school-based thalassaemia screening programme in Malaysia: a qualitative study
Journal of Community Genetics (2023)
-
Exploring the Gap Between Knowledge and Behavior Regarding Thalassemia Among University Students: A Cross-Sectional Study in the United Arab Emirates
Journal of Community Health (2022)
-
Extended family thalassemia screening as a feasible alternative method to be implemented in identifying carriers in West Java, Indonesia
Journal of Community Genetics (2022)
-
Premarital screening for genetic blood disorders — an integrated review on the knowledge and attitudes of Middle Eastern university students
Middle East Fertility Society Journal (2021)
